Pacira BioSciences, Inc.PCRXEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 17.50% | 8.1M | — | 2024-01-19 |
| The Vanguard Group | 10.98% | 5.1M | — | 2024-02-13 |
Insider Transactions
Net 90d: −$1.07M · buys $0 / sells $1.07MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-23 | Shawn Cross | Chief Financial Officer | Option exercise | 12.9K | $16.45 | $212.9K |
| 2026-04-23 | Shawn Cross | Chief Financial Officer | Sell (open market) | 12.9K | $25.16 | $325.6K |
| 2026-04-22 | Shawn Cross | Chief Financial Officer | Option exercise | 1.5K | $16.45 | $24.7K |
| 2026-04-22 | Shawn Cross | Chief Financial Officer | Sell (open market) | 1.5K | $25.01 | $37.5K |
| 2026-04-21 | Shawn Cross | Chief Financial Officer | Option exercise | 2.8K | $16.45 | $46.8K |
| 2026-04-21 | Shawn Cross | Chief Financial Officer | Sell (open market) | 2.8K | $25.01 | $71.2K |
| 2026-04-20 | Shawn Cross | Chief Financial Officer | Option exercise | 7.7K | $16.45 | $126.9K |
| 2026-04-20 | Shawn Cross | Chief Financial Officer | Sell (open market) | 7.7K | $25.14 | $193.9K |
| 2026-03-17 | SLONIN JONATHAN | Chief Medical Officer | Sell (open market) | 3.3K | $22.82 | $74.4K |
| 2026-03-17 | Mark Froimson | Director | Sell (open market) | 500 | $21.81 | $10.9K |
1–10 of 18
Page 1 / 2